| 1 |
34918545 | INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. | 2022 Mar |
3 |
| 2 |
35266116 | MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. | 2022 Mar |
1 |
| 3 |
35331964 | Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. | 2022 Jun |
1 |
| 4 |
35372088 | Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report. | 2022 |
2 |
| 5 |
35412115 | Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. | 2022 Apr |
1 |
| 6 |
35462930 | Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. | 2022 |
1 |
| 7 |
33438350 | Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib. | 2021 Mar |
1 |
| 8 |
33486418 | The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. | 2021 Mar |
1 |
| 9 |
33621951 | MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts. | 2021 Feb 17 |
2 |
| 10 |
33658860 | Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer. | 2021 |
2 |
| 11 |
33744716 | Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. | 2021 May |
1 |
| 12 |
33976623 | Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. | 2021 Jan-Apr |
1 |
| 13 |
34298655 | Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. | 2021 Jul 9 |
6 |
| 14 |
34397683 | Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report. | 2021 Jul 30 |
1 |
| 15 |
34498213 | Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. | 2021 Sep |
1 |
| 16 |
34532491 | A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with MET D1228N mutation: a case report. | 2021 Aug |
5 |
| 17 |
34575554 | Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. | 2021 Sep 15 |
1 |
| 18 |
34590012 | Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report. | 2021 Apr |
3 |
| 19 |
34590028 | Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib. | 2021 Jun |
3 |
| 20 |
31941753 | IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. | 2020 Apr |
1 |
| 21 |
33163272 | The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. | 2020 |
9 |
| 22 |
33186133 | Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification. | 2020 Nov 12 |
1 |
| 23 |
33324104 | Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. | 2020 |
1 |
| 24 |
30463991 | Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells. | 2019 Feb |
1 |
| 25 |
31122565 | A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treatment. | 2019 Jun |
1 |
| 26 |
29506987 | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. | 2018 Jul 1 |
2 |